San Diego’s Mapp Bio Receives $14.8 Million for Sudan Virus Therapy

Sep 30, 2018 | Mapp Bio, Sudan Virus Therapy

Bradley Fikes reports for the San Diego Union-Tribune that San Diego’s Mapp Biopharmaceutical, developer of an antibody therapy for Ebolahas received a $14.8 million federal contract to develop a similar treatment for the related Sudan virus. Mapp Bio has options for an additional $32 million under the contract with the Biomedical Advanced Research and Development Authority or BARDA, an agency in the Department of Health and Human Services. The goal is to advance the antibody therapy through an early clinical trial to assess safety.


Pin It on Pinterest